Clinical Trial Update: Patient Preference and Satisfaction With Insulin Glargine (Lantus) Solostar Pen vs Conventional Vial-Syringe Method of Lantus Injection Therapy in Patients With Type 2 Diabetes Mellitus [Phase 4]

View source ↗

Summary

Phase 4 trial comparing patient preference and satisfaction of Lantus insulin glargine delivered by Solostar Pen versus vial-syringe injections in Type 2 diabet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: COMPLETED | Results posted: 2013-07-30